Natural Agent in Prevention of Prostate Cancer
Natural Agent in Prevention of Prostate Cancer
批准号:
9094542
负责人:
Sanjeev Shukla
金额:
$20.68万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2018-06-30
关键词:
70-kDa Ribosomal Protein S6 KinasesAblationAdverse effectsAnti-Allergic AgentsAnti-Infective AgentsAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptosisApplications GrantsBindingBioavailableBioflavonoidBiological ModelsCCNE1 geneCDK2 geneCDK4 geneCancer EtiologyCancer PatientCatalytic DomainCell Cycle RegulationCell ProliferationCell SurvivalCell-Cell AdhesionCellsCessation of lifeChemopreventive AgentCitrus FruitClinicalColon CarcinomaComplexControl GroupsCyclin D1DU145DataDiseaseEmbryoEpithelialEpithelial CellsEventFOS geneFRAP1 geneFeedbackFibroblastsFlavanolGoalsGrowthHealthHumanImageImplantIn VitroInhibition of ApoptosisInsulin-Like Growth Factor IInterleukin-6Knock-outLNCaPMAP Kinase GeneMAPK3 geneMalignant neoplasm of ovaryMalignant neoplasm of prostateMesenchymalMessenger RNAMonitorMusNeoplasm MetastasisNormal CellNude MicePC3 cell linePRKCA genePathway interactionsPatientsPhosphorylationPhosphotransferasesPlant PreparationsPlant SourcesPlantsPlayPreventivePropertyProstateProteinsProto-Oncogene Proteins c-aktPublic HealthRaptorsReportingRodentRoleSeriesSignal TransductionSignaling MoleculeSirolimusStreamTacrolimus Binding Protein 1ATestingTranslationsTumor PromotionUnited StatesWI 38 cellWorkbcl-1 Genesc-myc Genescell growthcell motilitycell transformationclinically relevantdeguelineffective therapyhigh riskin vivoin vivo Modelinhibitor/antagonistmRNA Expressionmalemalignant breast neoplasmmenmouse modeloverexpressionpermanent cell linepreventprostate cancer cellprostate cancer cell lineprostate cancer modelprostate cancer preventionprotective effectprotein complexprotein expressiontargeted agenttumortumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The proposed study will determine the chemo-preventive potential of diosmetin, a natural plant flavanol, in regulating Rictor; the core constituent and critical protein in the function of mTORC2 (rapamycin- insensitive) protein complex to prevent prostate cancer progression. The role of Rictor has been reported in colon, breast and ovarian cancers. Circulating growth factors phosphorylates Rictor protein at Thr-1135 in prostate cancer cells, moreover, increased presence of rictor results in series of events including phosphorylation of PKCa and Akt molecules. Both these molecules play significant role in cell survival, cell adhesion, cell transformation and cell cycle regulation. It has been demonstrated that rapamycin, the known inhibitor of mTOR kinase pathway has no inhibitory effect on Rictor (mTORC2 main component). The urgent need is to identify an effective agent that can regulate Rictor and its associated events PKCa and Akt to prevent prostate cancer progression. Diosmetin has anti- inflammatory, anti-oxidants and anticancer effects. The proposed study will explore the preventive role of diosmetin in targeting Rictor, its phosphorylation and also its associated signaling events in prostate cancer. The in vitro and in vivo studies will determine whether diosmetin has potential to inhibit Rictor, its phosphorylation,
and additionally maintain rictor's presence to regulate kinase activities of PKCa and Akt at appropriate level, thereby resulting in reduced prostate cancer cell proliferation and tumor progression. Our long term goal is to develop diosmetin as safe and an effective chemopreventive agent for prostate cancer and to understand the role of Rictor in prostate cancer progression. Public Health Significance: There is an immediate need for an effective and clinically relevant strategy to inhibit prostate cancer, with minimal side-effects. Hereby using a natural agent from citrus fruits and herbal preparations, the potential of diosmetin will be tested
against prostate cancer. Since prostate cancer is the second largest killer in the United States males, reducing deaths from this deadly form of disease is urgently needed.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2019
期刊:
International journal of cell biology and physiology
影响因子:
--
作者:
[I. Isali;Mohammed Adel Ali Al-Sadawi;A. Qureshi;Ahmad O Khalifa;M. K. Agrawal;S. Shukla]
通讯作者:
I. Isali;Mohammed Adel Ali Al-Sadawi;A. Qureshi;Ahmad O Khalifa;M. K. Agrawal;S. Shukla
DOI:
10.3892/ijo.2018.4407
发表时间:
2018-08
期刊:
International journal of oncology
影响因子:
5.2
作者:
[Oak C, Khalifa AO, Isali I, Bhaskaran N, Walker E, Shukla S]
通讯作者:
Shukla S
DOI:
10.2741/e830
发表时间:
2018-03-01
期刊:
Frontiers in bioscience (Elite edition)
影响因子:
--
作者:
[Patel R, Khalifa AO, Isali I, Shukla S]
通讯作者:
Shukla S
DOI:
10.3390/jcm10204741
发表时间:
2021-10-15
期刊:
Journal of clinical medicine
影响因子:
3.9
作者:
[Pakradooni R, Shukla N, Gupta K, Kumar J, Isali I, Khalifa AO, Shukla S]
通讯作者:
Shukla S
SerpinA6 Involvement in Prostate Cancer
-
批准号:9904589
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2019
-
负责人:Sanjeev Shukla
-
依托单位:
Natural Agent in Prevention of Prostate Cancer
-
批准号:8956789
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2015
-
负责人:Sanjeev Shukla
-
依托单位:
Effect of Rhamnetin on Oxidative Stress and Prostate Cancer
-
批准号:8539586
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2012
-
负责人:Sanjeev Shukla
-
依托单位:
Effect of Rhamnetin on Oxidative Stress and Prostate Cancer
-
批准号:8399168
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2012
-
负责人:Sanjeev Shukla
-
依托单位:
FOXO: A Target for Prostate Cancer Prevention
-
批准号:7894678
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2009
-
负责人:Sanjeev Shukla
-
依托单位:
FOXO: A Target for Prostate Cancer Prevention
-
批准号:7750415
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2009
-
负责人:Sanjeev Shukla
-
依托单位:
海外基金